NCT04902872 - Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions

Solid Tumor, AdultEpithelial Ovarian CancerSmall Cell Lung CarcinomaBreast CancerColorectal CancerPancreas CancerAppendix CancerNon-small Cell Lung CancerGastric CancerEsophagus CancerUrothelial CarcinomaSarcoma

Interventions

DRUG

CBX-12

CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety

Trial Locations (4)

77030

MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

78758

NEXT Oncology, Austin

06511

Yale Cancer Center, New Haven